Top

BY Clayton Boldt, Ph. D.

Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits in new indications can be a challenging discovery process.

A team of researchers led by MD Anderson and the IRCCS Regina Elena National Cancer Institute in Rome have used a novel computer-aided drug discovery approach to identify decitabine, an FDA approved therapy for myelodysplastic...

Gene expression signature identified in the study allows pancreatic cancers stratification based on KRAS dependency

BY Ron Gilmore

The addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid...

BY Clayton R. Boldt, Ph.D.

MD Anderson’s Moon Shots Program™ was established to bring teams of world-class clinicians and researchers together in order to rapidly advance...

BY Ron Gilmore

Tomas Sandoval was about to become a father for the second time in June 2014, when he was devastated to learn he had non-Hodgkin lymphoma, a type of cancer that starts in the white blood cells. The College Station, Texas, resident underwent a stem cell transplant at MD Anderson that kept his disease in check – for a year.

In June 2015, doctors discovered a large chest mass that revealed Sandoval’s cancer had spread...

Naval Daver, M.D., leukemia

BY Scott Merville

Natural killer cells sound menacing, but they play a friendly role in keeping us healthy. And they might do much more in stopping...

BY Ron Gilmore

What if you or a loved one had cancer but were denied access to a research study testing a poten-tially beneficial treatment?

This...